Skip to main content
PepStack
Blutwerte · Marker

IL-6

Interleukin-6 · Interleukin 6

EntzündungsmarkerZeitabhängig
Einheit:
pg/mL

IL-6 quantifies the concentration of interleukin-6, a cytokine involved in inflammation and immune response.

Reference Ranges

Reference
0–7pg/mL
0
7
LowNormalHigh
Reference
Unit · pg/mL

Levels can vary based on age, sex, and health status. Fasting and time of day may influence results.

Overview

Übersicht

Interleukin-6 (IL-6) is a cytokine involved in the regulation of immune responses, inflammation, and hematopoiesis. It is produced by various cell types, including leukocytes, adipocytes, and endothelial cells. IL-6 plays a critical role in the acute phase response, stimulating the production of acute-phase proteins like C-reactive protein (CRP) in the liver. Clinically, IL-6 is a significant biomarker for inflammatory conditions and cardiovascular diseases. Elevated IL-6 levels are associated with increased risk of atherosclerosis, cardiogenic shock, and other cardiovascular complications. It is also implicated in cancer progression, particularly in inflammation-induced malignancies like cholangiocarcinoma. In the context of athletic performance and biohacking, IL-6 is of interest due to its role in muscle repair and adaptation to exercise. However, chronic elevation may indicate overtraining or systemic inflammation, which can negatively impact performance and recovery. Researchers observed that IL-6 levels can be influenced by various factors, including stress, infection, and exercise. Time-of-day and fasting status may also affect measurements, necessitating standardization in testing protocols to ensure accurate interpretation.

Klinische Bedeutung

Elevated IL-6 levels indicate systemic inflammation and are associated with cardiovascular disease, infection, and certain cancers. Reduced levels are less commonly discussed but may reflect immunosuppression.

Dynamics

Trend Interpretation

Rising Values

Progressively rising IL-6 levels suggest worsening inflammation or disease progression. Re-test every 4 weeks if outside the optimal range.

Falling Values

Decreasing IL-6 levels may indicate improvement in inflammatory status or effective treatment.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Chronic inflammation
  • Infection
  • Cardiovascular disease
  • Cancer
  • Autoimmune disorders
Cause

Low Levels

  • Immunosuppression
  • Certain medications
  • Chronic stress
  • Nutritional deficiencies
Protocol

How to Optimize

Lever

Lifestyle

  • Regular moderate exercise
  • Stress management techniques
  • Adequate sleep
Lever

Nutrition

  • Anti-inflammatory diet
  • Omega-3 fatty acids
  • Increased fruit and vegetable intake
Lever

Supplementation

  • Omega-3 supplements
  • Curcumin
  • Resveratrol

Note:

Consult a healthcare provider before starting new supplements, especially if on medication.

Testing Guidelines

✓Fasting Not Required
🕐Time-Sensitive

IL-6 levels may vary throughout the day; morning tests are recommended for consistency.

Testing Frequency

Annually for general health monitoring, more frequently if managing chronic conditions.

Interfering Factors

  • Recent intense exercise
  • Acute infection
  • Stress

Related Peptides & Hormones

C Reactive Protein

Correlated with

hormone or peptide

Open Research Questions

Current research suggests that the perioperative kinetics of IL-6 in cardiac surgical patients remain insufficiently understood, with unclear influencing factors and clinical implications. Researchers have not yet established optimal reference ranges for IL-6 in various conditions, particularly in cardiogenic shock and cholangiocarcinoma. Additionally, clinical questions remain unanswered regarding the efficacy of IL-6-targeted therapies and the specific mechanisms linking IL-6 to poor prognostic outcomes across different inflammatory diseases.

42 Research Publications

1,245

Total Citations

16

Human/RCT

3.8

Avg. Influence

2025

Latest

Sort
Filter
#01

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.

ReviewInfluence25.0
583
This review examined the role of interleukin-6 (IL-6) in cardiovascular disease and its potential as a biomarker for vascular risk. Researchers found that IL-6 signaling is linked to atherogenesis and suggested that inhibiting IL-6 could provide vascular protection. The study also highlighted the development of ziltivekimab, an IL-6 ligand inhibitor, for use in high-risk cardiovascular patients.
View on PubMed
#02

Why C-reactive protein is one of the most requested tests in clinical laboratories?

ReviewInfluence8.0
147
This study explored the significance of C-reactive protein (CRP) as a marker of inflammation, which is influenced by interleukin-6 (IL-6). Researchers found that CRP is widely used in clinical laboratories for diagnosing inflammatory conditions and has gained attention as a biomarker for COVID-19 severity. The study emphasized the importance of CRP in managing systemic inflammatory diseases.
View on PubMed
#03

The Role of Interleukin-6 in Castleman Disease.

ReviewInfluence2.0
61
This review highlighted the significance of interleukin-6 (IL-6) in Castleman disease, particularly its role in the hyperfunction of IL-6 in affected lymph nodes. Researchers found that treatments targeting IL-6, such as tocilizumab, improve symptoms in patients with multicentric Castleman disease. The study emphasizes IL-6's central role in the disease's pathogenesis.
View on PubMed
#04

Organic Electrochemical Transistor Aptasensor for Interleukin-6 Detection.

In VitroInfluence1.0
46
This study demonstrated a new biosensor for detecting interleukin-6 (IL-6), a biomarker associated with inflammation and severe COVID-19. Researchers achieved a detection range from picomolar to nanomolar concentrations and confirmed the sensor's selectivity against other cytokines. The biosensor could improve IL-6 detection in clinical settings.
View on PubMed
#05

Interleukin-6 as a prognostic biomarker of clinical outcomes after traumatic brain injury: a systematic review.

Meta-AnalysisInfluence1.0
44
Researchers conducted a systematic review on interleukin-6 (IL-6) as a prognostic biomarker in traumatic brain injury (TBI). They found that elevated IL-6 levels were associated with poorer clinical outcomes, although results varied across studies.
View on PubMed
#06

The Role of IL-6 in Neurodegenerative Disorders.

Review
40
This review summarized the role of interleukin-6 (IL-6) in neurodegenerative disorders, noting its involvement in neuroinflammation. Researchers found that high levels of IL-6 are frequently associated with these disorders, suggesting its potential as a biomarker for disease progression and prognosis. The study emphasizes the need for further research on IL-6's signaling pathways.
View on PubMed
#07

Interleukin-6 and amyotrophic lateral sclerosis.

HumanInfluence2.0
40
This study investigated the relationship between interleukin-6 (IL-6) levels and clinical staging in amyotrophic lateral sclerosis (ALS) patients. Researchers found that while IL-6 levels were elevated in ALS patients, variability in levels was noted, and a correlation was observed between IL-6 and respiratory dysfunction. The study highlights the influence of age and respiratory factors on IL-6 levels.
View on PubMed
#08

The Role of IL-6 in Ischemic Stroke.

ReviewInfluence2.0
39
This article explored the role of interleukin-6 (IL-6) in ischemic stroke. Researchers found that IL-6 is a significant inflammatory mediator during the acute phase of a stroke and may serve as a reliable prognostic factor for patient outcomes. The study highlighted the need for further research on IL-6's impact on stroke severity.
View on PubMed
#09

Clinical significance of cytokine measurement for detection of meningitis.

Human
37
Researchers measured interleukin-6 (IL-6) levels in cerebrospinal fluid from meningitis patients. They found that IL-6 was elevated in both aseptic and bacterial meningitis, indicating its potential as a rapid diagnostic marker. This study suggests that cytokine measurement could enhance meningitis diagnosis.
View on PubMed
#10

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

ReviewInfluence1.0
30
This study investigated the relationship between lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6) in the context of atherosclerotic cardiovascular disease (ASCVD). Researchers found that IL-6 receptor inhibitors can lower Lp(a) levels and may have dual effects on inflammation and apolipoprotein synthesis, suggesting potential benefits in ASCVD prevention. The study calls for more trials to clarify these interactions.
View on PubMed

Clinical Trials (9)

9

Total Trials

1,503

Total Enrolled

Impact of HMB Supplementation on Inflammation and Outcomes in Head and Neck Cancer

NCT07675421RECRUITING
Sponsor

Federal University of Minas Gerais

Enrollment

66

Started

2026

Primary outcome

Inflammatory Biomarkers: Serum interleukin-6 (IL-6) concentratio

Head and Neck Cancers

Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion

NCT07754942NOT_YET_RECRUITING
Sponsor

Zhongshan Hospital Xiamen University

Enrollment

50

Started

2026

Primary outcome

Trans-Thrombus Interleukin-6 Gradient

Acute Ischemic StrokeLarge Vessel Occlusion

Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial

NCT07497555RECRUITING
Sponsor

Universidad Autonoma de Nuevo Leon

Enrollment

50

Started

2025

Primary outcome

Change in interleukin-6 (IL-6) levels

Overweight (BMI > 25)

Beef and Plant Burger Metabolomics Study

Sponsor

Utah State University

Enrollment

36

Started

2023

Primary outcome

Inflammatory cytokine biomarker (IL-6) concentrations in plasma samples

Inflammatory Response

Measurment of Interleuukin-6 at Exhaled Breath Condensate of Covid-19 Patients and Post Covid-19 Patients With Lung Fibrosis Randomized Controlled Study

Sponsor

Ministry of Health, Saudi Arabia

Enrollment

60

Started

2022

Primary outcome

measurement of interleukin-6 at exhaled condensate in covid-19, postcovid-19 ,healthy subjects

Inflammatory ResponseImmunological AbnormalityCOVID-19

Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Enrollment

140

Started

2021

Primary outcome

DAS28-C-reactive Protein (CRP) change

Rheumatoid ArthritisIdiopathic Juvenile ArthritisGiant Cell ArteritisStill Disease

Inflammation and Co-Infections in D²EFT

NCT04183738Phase 4WITHDRAWN
Sponsor

Kirby Institute

Enrollment

0

Started

2021

Primary outcome

Change from baseline in IL-6 level at week 48

HIV-infection/AidsHuman Herpesvirus 4 InfectionsCytomegalovirus InfectionsHuman Herpesvirus 8 InfectionHuman Papilloma Virus

Danger Response in Polytrauma Patients

Sponsor

University of Ulm

Enrollment

1,000

Started

2014

Primary outcome

Interleukin-6 (IL-6) plasma concentration

Multiple Trauma

Inflammatory Response in Aortic Valve Replacement

NCT02324140COMPLETED
Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

101

Started

2012

Primary outcome

Inflammatory response, as determined by whole blood analysis of inflammatory biomarkers (IL-6, CRP, TNF alpha, CD62L)

InflammationSystemic Inflammatory Response SyndromeThoracic SurgeryAortic Valve Stenosis

Publication Trend

Research publications about IL-6 over time

7total
1
'19
3
'20
1
'21
1
'23
1
'25

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer